Abstract
We have carried out laboratory and clinical studies on sulbactam/ampicillin (SBT/ABPC).
The results are summarized as follows.
SBT/ABPC was given by 30-minute drip infusion to 1 child at a single dose of 15mg/kg and to 2 children at a single dose of 30 mg/kg. After the 30-minute drip infusion, peak serum levels of ABPC (SBT) obtained for the 2 dose levels were 18.0μg/ml (12.4μg/ml) for the former dose level and 81.0μg/ml (53.7μg/ml) and 300μg/ml (200μg/ml) for the latter at the end of injection, and half-lives were 0.84 hour (0.82 hour) for the former and 0.96 hour (1.44 hours) and 0.93 hour (1.19 hours) for the latter. In another trial, SBT/ABPC was given to 1 child at a single do,se of 60 mg/kg. After the 30-minute drip infusion, peak serum level of ABPC (SBT) was 82.3,ug/ml (45.9μg/ml), and half-life was 1.20 hours (1.36 hours).
The urinary excretion rates of ABPC (SBT) were 51.3% (49.5%), 55.8±10.4% (65.3±9.1%), 74.0% (76.1%) up to 6 hours after the 30-minute drip infusion of 15 mg/kg, 30 mg/kg and 60mg/kg, respectively.
Treatment with SBT/ABPC was made in 21 cases of pediatric bacterial infections: 8 cases of tonsillitis, 4 cases of bronchitis, 3 cases of pneumonia and 1 case each of pharyngitis, peritonsillar abscess, lymphadenitis, impetigo, abscess and urinary tract infection. Results obtained were excellent in 14 cases, good in 7 cases.
No significant side effect due to the drug was observed in any cases except 1 case of fever and rash.
